title: The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation.
abstract: OBJECTIVE
  To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients.
  
  
  METHODS
  Inception cohort study.
  
  
  METHODS
  An academic medical center.
  
  
  METHODS
  Four hundred seventy-two patients aged 65 and older who were followed as part of a larger study assessing stroke prevention in patients with atrial fibrillation.
  
  
  METHODS
  Prescription drug expenditures were calculated for each patient in the cohort under three conditions: the 2006 AARP-endorsed prescription drug plan, the Medicare standard benefit, and no prescription drug coverage.
  
  
  RESULTS
  Total prescriptions drug costs were lower under the AARP plan, yet patients paid a similar percentage of total costs under the AARP plan and the Medicare standard benefit. Using different cost assessments, 27% to 46% of patients entered the "doughnut hole" in the AARP plan, and 3% to 11% emerged to receive catastrophic coverage.
  
  
  CONCLUSIONS
  Both the AARP-sponsored and standard Medicare Part D prescription drug benefit programs offer significant savings to enrollees. A greater savings is achieved under the private AARP drug insurance plan, largely due to greater discounts reflected in the negotiated drug prices. A substantial portion of enrollees enter but do not emerge from the coverage gap.
authors.affiliation: Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia, USA.
authors.forename: Carmella
authors.initials: C
authors.lastname: Evans-Molina
authors.forename: Susan
authors.initials: S
authors.lastname: Regan
authors.forename: Lori E
authors.initials: LE
authors.lastname: Henault
authors.forename: Elaine M
authors.initials: EM
authors.lastname: Hylek
authors.forename: Gregory R
authors.initials: GR
authors.lastname: Schwartz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016527:Drug Costs / Q000706:statistics & numerical data*; D011307:Drug Prescriptions / Q000191:economics*; D005260:Female; D005500:Follow-Up Studies; D005102:Health Expenditures; D006801:Humans; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D008297:Male; D006278:Medicare / Q000191:economics*; D011306:Prescription Fees; D012189:Retrospective Studies; D020521:Stroke / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D014481:United States